zintick

Alnylam Pharmaceuticals ALNY

Alnylam Pharmaceuticals, Inc. · Nasdaq · Pharmaceutical Preparations

$165.00-5.17%close on Oct. 30, 2026 · volume 6.9M · Yahoo Finance

Price, last 49 sessions

$200.00$250.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 30, 2026 · high $267.40 · low $165.00 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 2, 2026Bryan Supran
EVP, CLO and Secretary
Sold1,758$226.88$398,855

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 7 →
  • SCHEDULE 13GOct. 30, 2026, 1:36 p.m. ETView on SEC.gov
  • 10-QOct. 29, 2026, 8:20 a.m. ETView on SEC.gov
  • 8-KOct. 29, 2026, 8:16 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedAlnylam Q3 2026 Non-GAAP Diluted EPS of $16.26 Tops $2.25 Consensus on $1.9 Billion Tax Benefit; Revenue of $1.46 Billion Beats $1.43 Billion Estimate

  • 4Oct. 6, 2026, 4:12 p.m. ETView on SEC.gov
  • 4Sept. 22, 2026, 4:07 p.m. ETView on SEC.gov
  • 10-QJuly 30, 2026, 8:11 a.m. ETView on SEC.gov
  • 8-KJuly 30, 2026, 8:06 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits